Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Cisplatin + NTX-301|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Cisplatin||Platinol||CDDP||Chemotherapy - Platinum 7||Platinol (cisplatin) is a platinum based chemotherapeutic, which is FDA approved for bladder, ovarian, and testicular cancers (NCI Drug Dictionary).|
|NTX-301||NTX 301|NTX301||DNMT1 inhibitor 4||NTX-301 inhibits DNMT1, potentially leading to reduced tumor growth and improved survival (PMID: 35410412; J Clin Oncol 40, no. 16_suppl (June 01, 2022) TPS7077).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT04851834||Phase Ib/II||Cisplatin + NTX-301 NTX-301 NTX-301 + Temozolomide Carboplatin + NTX-301||NTX-301 Monotherapy in Advanced Solid Tumours and in Combination With Platinum-based Chemotherapy in Advanced Ovarian & Bladder Cancer and in Combination With Temozolomide in High-grade Glioma||Terminated||1|